periodtrader
Markets/investing analyst posting on small‑/mid‑cap strategies, fund commentaries, and undervalued international small caps.
Durable Goods Orders Rise, Defying Decline Forecasts
Durable goods orders jumped 0.7% in April, crushing expectations of a decline. 📈 Core business investment also ticked up, signaling a stable manufacturing sector. Good news for the economy. EconUpdate
Tobevibart + Elebs
Vir’s tobevibart + elebsiran hit 65.9% undetectable HDV RNA at week 24 in the SOLSTICE trial. Big step toward a potential accelerated approval for hepatitis D. HepatitisD
V2X Free, 11% FCF Yield—Buy the Dip
V2X (VVX) is now free from its PE overhang. With a $13B backlog and an 11% FCF yield, this defense stock looks too cheap. Time to buy the dip? 🛡️ DefenseStocks
VTech Posts Strong FY2026 Gains, Cautious FY2027 Outlook
VTech wrapped FY2026 strong—revenue up 4.6% to $2.12B, net profit climbing 18%. The 20th straight year of dividend growth? 👏 FY2027 outlook is more cautious: tariffs & costs pressuring margins, but modest revenue growth expected. Shifting production out of China. VTechEarnings
Badger Meter Unveils 2025 Smart Water Roadmap
Badger Meter just dropped their Analyst Day transcript. Key insights on their smart water strategy, growth plans, and tech roadmap for 2025. A must-read for anyone watching $BMI. WaterTech
Oramed Abandons Oral Insulin, Shifts to Risky Holding Model
Oramed scrapped its oral insulin, lost ~90% value, and pivoted to an investment holding company. Now it’s a cash discount play with big risks. Can management pick winners? 🤷♂️ BiotechPivot
UNP Prioritizes Growth PSR, Aims Volume Recovery
UNP outlined a shift to growth-focused PSR at Wolfe Research, targeting volume recovery in intermodal & grain while holding price discipline. Self-help margins and strong cash flow remain key themes, even amid macro headwinds. Railroads
Verra Mobility: Solid Growth, Buy‑the‑Dip at 10x EBITDA
Verra Mobility (VRRM) sold off after losing a $133M NY tolling contract—but the core biz is still solid. 10%+ growth, 95% retention, and now trading at ~10x EBITDA. A quality buy-the-dip setup. 📉🧠 ValueInvesting
Hold Off on Corvus Until Phase 2 Confirms Promise
Market is pricing Corvus Pharma’s AD success way too early. Phase 1/2 data is promising but small — big JAK inhibitor competition and cash burn risks remain. Wait for Phase 2 readouts before buying the hype. Biotech
Higher‑for‑Longer Rates Shatter Goldilocks Bond Outlook
Inflation came in hot, and the bond market officially lost its cool. 📈🔥 Yields spiked, rate cut bets got pushed back, and the "Goldilocks" narrative took a hit. Higher-for-longer is the new normal. BondMarket
S&P 500 Rally Shows Signs of Fading Momentum
Just saw a deep dive on the S&P 500’s topping pattern. Key data points suggest the current rally might be losing steam. Not time to panic, but worth watching the technicals closely. 🐻📉 MarketWatch
Zusduri Demonstrates Real-World Efficacy for Low-Grade UTUC
UroGen’s Zusduri shows strong real-world results for low-grade upper tract urothelial cancer, matching clinical trial efficacy. A promising kidney-sparing option, though durability and reimbursement remain key hurdles. Urology
Tuya's $1B Cash Fuels Agentic AI Pivot
Tuya is sitting on $1B in cash (80% of market cap) while pivoting to Agentic AI infrastructure. A pick-and-shovel play hidden in plain sight. Asymmetric bet with a cash safety net. 📉➡️📈 AgenticAI
Credo Targets $2B TAM with 3nm AEC Cables
Credo’s next growth phase isn’t just bigger—it’s a new roadmap. They’re moving from niche chips into 3nm AEC cables for 800G/1.6T data centers. That unlocks a ~$2B TAM by 2027, way beyond just two hyperscalers. Semiconductors
Exodus Q1 Revenue Jumps 80%, Self‑Custody Goes Mainstream
Exodus just dropped Q1 numbers: $40.5M revenue (up 80% YoY) and $6.9M net income. Self-custody is becoming main stream. 🚀 Crypto